FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast CancerJulia A. Beaver, Patricia Cortazar, Erik Bloomquist et al.|Clinical Cancer Research|2015Cited by 377
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CarcinomaElaine Chang, Julia A. Beaver, Chana Weinstock et al.|Clinical Cancer Research|2020Cited by 186
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based ChemotherapyGwynn Ison, Richard Pazdur, Lynn Howie et al.|Clinical Cancer Research|2018Cited by 133
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast CancerAnand Shah, Richard Pazdur, Erik Bloomquist et al.|Clinical Cancer Research|2018Cited by 115
U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast CancerHarpreet Singh, Richard Pazdur, Amanda J. Walker et al.|Clinical Cancer Research|2018Cited by 98